Onconetix (ONCO) vs SciSparc (SPRC)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Onconetix is the larger company by market cap ($3.4 million vs $2.6 million), about 1.3 times the size. On valuation, Onconetix trades at a lower trailing P/E (0.0x vs 0.0x for SciSparc).
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ONCO | SPRC |
|---|---|---|
| Share price | $0.6543 | $4.43 |
| Market cap | $3.43M | $2.57M |
| 1-day change | +9.56% | -4.53% |
| P/E ratio (TTM) | 0.00 | 0.02 |
| EPS (TTM) | $310.39 | $248.24 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $207.00 | $43.65 |
| 52-week low | $0.58 | $2.98 |
| Distance from 52-week high | -99.68% | -89.85% |
| Average volume | 2.96M | 179.62K |
| Shares outstanding | 5.24M | 580.97K |
| Employees | 2 | 3 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- SciSparc trades at a higher earnings multiple (0.0x vs 0.0x trailing P/E).
About Onconetix
ONCO stock →Onconetix, Inc., a biotechnology company, focuses on the research, development, and commercialization of solutions for men's health and oncology in the United States, the European Union, and Non-European Union. The company offers Proclarix, an in vitro protein-based blood diagnostic test for prostate cancer.
Health Care · Biotechnology: Pharmaceutical Preparations · 2 employees
About SciSparc
SPRC stock →SciSparc Ltd., a clinical-stage pharmaceutical company, develops drugs based on cannabinoid therapies. Its drug development programs include SCI-110 for the treatment of Tourette syndrome and Alzheimer's disease and agitation; SCI-210 for the treatment of autism spectrum disorder and status epilepticus; and CannAmide, an anti-inflammatory and chronic pain solution.
Health Care · Biotechnology: Pharmaceutical Preparations · 3 employees
ONCO vs SPRC FAQ
Which is bigger, Onconetix or SciSparc?
Onconetix (ONCO) is larger, with a market capitalization of $3.43M compared with $2.57M for SciSparc (SPRC).
Which has the lower P/E ratio, ONCO or SPRC?
ONCO has the lower trailing P/E at 0.0, versus 0.0 for SPRC. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Are Onconetix and SciSparc in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.